PPARG and Hepatic fibrosis: Both hBM-MSCs and hBM-MSCs-Ex treatment significantly inhibited the expression of PPARγ, Wnt3a, Wnt10b, β-catenin, WISP1, Cyclin D1, α-SMA, and Collagen I in both HSCs and liver fibrosis tissues (Fig. 5b, d; p < 0.005, p < 0.001).